Trial Profile
A Phase 1 Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-ANG3 in Adult Healthy Volunteers and in Dyslipidemic Patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Zodasiran (Primary)
- Indications Dyslipidaemias
- Focus Adverse reactions; First in man
- Sponsors Arrowhead Pharmaceuticals
- 20 Sep 2021 Status changed from active, no longer recruiting to completed.
- 08 Dec 2020 Planned End Date changed from 30 May 2020 to 28 May 2021.
- 08 Dec 2020 Planned primary completion date changed from 30 May 2020 to 28 May 2021.